# Effect of Intrapulmonary Recombinant Human Activated Protein C (APC) on Coagulation and Inflammation After Lipopolysaccharide (LPS)

> **NCT00943267** · NA · COMPLETED · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 52 (estimated)

## Conditions studied

- Pneumonia
- Lipopolysaccharides

## Interventions

- **DRUG:** Drotrecogin alpha
- **DRUG:** Saline (NaCl 0.9%)
- **DRUG:** Endotoxin
- **PROCEDURE:** Bronchoscopy
- **PROCEDURE:** Blood sampling

## Key facts

- **NCT ID:** NCT00943267
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-08
- **Final completion:** 2011-03
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2011-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00943267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00943267, "Effect of Intrapulmonary Recombinant Human Activated Protein C (APC) on Coagulation and Inflammation After Lipopolysaccharide (LPS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00943267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*